What is Androgenetic Alopecia Treatment Market?
It is estimated that androgenetic Alopecia affects up to 80% of men and 50% of women in the course of their life. Androgenetic alopecia is a common form of hair loss due to genetic reasons in both men and women. In this condition receding hairline and gradual disappearance of hair from the crown and frontal scalp. United States Food and Drug Administration (FDA) has approved only two drugs for the treatment of androgenetic alopecia that includes minoxidil and finasteride. Numerous new therapies are emerging or being studied as treatment options for androgenetic alopecia.
The market study is being classified by Type (Drugs (Minoxidil, Dutasteride, Finasteride and Others), Low-level Laser Therapy, Microneedling and Hair Transplantation and Others) and major geographies with country level break-up.
Histogen Inc. (United States), Daiichi-Sankyo Co., Ltd. (Japan), Lexington International LLC (United States), Vitabiotics (United Kingdom), Die Vita-Cos-Med Klett-Loch GmbH (Germany), PureTech Health (United States), Sun Pharmaceutical Industries Ltd. (India), Merck & Co., Inc. (United States), Dr. Reddy’s Laboratories (India), Follica, Inc. (United States), Cipla (India) and Johnson & Johnson (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Ales Group (France) and Ranbaxy Laboratories Ltd. (India).
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Androgenetic Alopecia Treatment market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Androgenetic Alopecia Treatment market by Type, Application and Region.
On the basis of geography, the market of Androgenetic Alopecia Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increased Prevalence of Androgenetic Alopecia among People
- Development of New Diagnostic Centre and Hospitals
- Increase in Healthcare Expenditure in Developing Regions such as China and India
- Increased Awareness about Androgenetic Alopecia Treatment
- Lack of Complete Cure for Androgenetic Alopecia Treatment
- Growth in the Healthcare Industry Worldwide
- Development of Healthcare Infrastructure in Emerging Economies
- Stringent Government Rules and Regulations
Key Target AudienceAndrogenetic Alopecia Treatment Providers, Emerging Companies, Research Professionals and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase